A Phase 2 interventional study of Full-Spectrum Cannabidiol (CBD) and Broad-Spectrum Cannabidiol (CBD) in Alcohol Use Disorder, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by University of Colorado, Denver · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing cannabidiol in Alcoholism — 4 open to participants now, 4 under way, 2 of them phase 3. Cannabidiol · Alcoholism.
Among the 12 studies testing cannabidiol in Alcoholism, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 2, and was the 12th registered.
1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.
Browse Alcoholism studies →4 of the 12 studies testing cannabidiol in Alcoholism are open now, in 2 countries. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 21–65
Central Institute of Mental Health, Mannheim · Sites in Germany
Ages 18–70
University of Colorado, Denver · Sites in United States
Ages 21+
By country, each count listing its studies:
Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 2
First in 2019; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 150 is above the median of 88 across 1,430 interventional studies indexed under Alcoholism.
Median enrollment 49 across the 12 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 7 most frequent:
University of Colorado, Denver is the lead sponsor of 1,544 studies on the registry; 318 are open to participants now.
Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.
16 studies in Alcoholism by University of Colorado, Denver: 5 open now, 5 under way, 1 of them phase 3. Of 9 finished, 2 (22%) have results posted.
Among the 16 studies in Alcoholism by University of Colorado, Denver, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 in phase 2, and was the 15th registered.
University of Colorado, Denver’s Alcoholism studies by the year they started, since 2008.
1 of the studies testing cannabidiol in Alcoholism that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05613608Phase 3University of Colorado, DenverAlcohol Use Disorder and Cannabidiol | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing cannabidiol in Alcoholism, from their registry updates:
Among University of Colorado, Denver’s 16 in Alcoholism:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn how CBD affects drinking in people who drink alcohol regularly. Researchers want to see if CBD can help people drink less and reduce problems related to alcohol use.
Your participation will include up to five in-person visits over about 13 weeks, including a screening visit, a visit to get your medication, a midpoint visit, an experimental lab session, and a final follow-up visit. You will be assigned to a study medication which you will take daily for 8 weeks while completing daily surveys and weekly virtual check-ins with the research team. During the experimental lab session visit, you will be offered alcohol to drink at the bar lab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Not everyone will qualify to be in the study. Other inclusion and exclusion criteria will be evaluated by the study team.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will take 200 mg of full-spectrum CBD (\[fsCBD\] CBD that contains \<0.3% THC) daily for 8 weeks. The total dose is split into a morning and evening dose, such that participants in the fsCBD condition will take approximately 100mg fsCBD in the morning (2 capsules) and 100mg fsCBD in the evening (2 capsules).
Drug: Full-Spectrum Cannabidiol (CBD)
Subjects will take 200 mg of broad-spectrum CBD (\[bsCBD\] CBD that contains no THC) daily for 8 weeks. The total dose is split into a morning and evening dose, such that participants in the bsCBD condition will take approximately 100mg bsCBD in the morning (2 capsules) and 100mg bsCBD in the evening (2 capsules).
Drug: Broad-Spectrum Cannabidiol (CBD)
Subjects will take a matching placebo solution (100% Hemp Seed Oil) daily for 8 weeks. The total dose is split into a morning and evening dose, such that participants in the condition will take approximately 100mg hemp seed oil in the morning (2 capsules) and 100mg hemp seed oil in the evening (2 capsules).
Drug: Placebo
Dose: Approximately 200mg of full-spectrum CBD (\<0.3% THC) Active Ingredients: Full spectrum hemp extract Other Ingredients: Hemp seed oil, glycerin, gelatine.
Also known as: Hemp-derived, full-spectrum cannabidiol, Ecofibre USA/Ananda Hemp
Dose: Approximately 200mg of broad-spectrum CBD, (0% THC) Active Ingredients: Broad spectrum hemp extract Other Ingredients: Hemp seed oil, glycerin, gelatine.
Also known as: Hemp-derived, broad-spectrum cannabidiol, Ecofibre USA/Ananda Hemp
Active Ingredients: N/A Other Ingredients: Hemp seed oil, glycerin, gelatine.
Also known as: 100% Hemp Seed Oil, Ecofibre USA/Ananda Hemp
Alcohol Self-Administration During the Bar Lab Task
Number of drinks (between 0-8) subjects choose to self-administer during the Bar Lab Alcohol Self-Administration Task at the week 8 study visit.
Time frame: Week 8
Change in Self-Report of Drinking Behavior (Drinks Per Drinking Day)
Drinks Per Drinking Day (DPDD) during the 12-week study period as reported on Timeline Follow Back at Baseline (prior to treatment), Week 4, Week 8, and Week 12.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Phosphatidylethanol (PEth)
Phosphatidylethanol (PEth) concentration in blood samples collected at Baseline (prior to treatment), Week 4, Week 8, and Week 12.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Negative Emotionality ANA Domain Score
This summary score will be calculated for change from baseline to follow-up for each of the four ANA Negative Emotionality Measures (Beck Depression Inventory-II, Beck Anxiety Inventory, State-Trait Anxiety Inventory and Drinker Inventory of Consequences-2R) . We will first subtract baseline raw scores from follow-up raw scores for each measure. The summary score will be comprised of the average of the standardized Z scores of the change scores created for each of the four measures. Z scores will range from -3 to 3 after adjusting for outliers, with higher average Z scores indicating a worse outcome.
Time frame: Baseline, Week 8
Change in Gut Microbial Diversity
Gut microbial diversity from fecal samples collected at Baseline (prior to treatment) and Week 8.
Time frame: Baseline, Week 8
Change in Gut Permeability (Lipopolysaccharide Binding Protein [LBP])
Lipopolysaccharide Binding Protein levels in blood samples collected at Baseline (prior to treatment) and Week 8.
Time frame: Baseline, 8 Weeks
Change in Gut Permeability (CD14)
CD14 levels in blood samples collected at Baseline (prior to treatment) and Week 8.
Time frame: Baseline, 8 Weeks
Plan to share: Yes — Investigators will submit all de-identified individual level phenotypic human subjects data from this project to the National Institute on Alcohol Abuse and Alcoholism (NIAAA) Data Archive, which is part of the National Institutes of Mental Health (NIMH) Data Archive (NDA). The project also involves collection of human specimens (fecal samples) which will generate non-human genomic data. Specifically, investigators plan to generate 300 (150 subjects x 2 timepoints) human gut microbiota metagenomes (i.e., gut microbiome). Deidentified genomic data (microbiome sequencing from the fecal samples) will be uploaded to the appropriate data repository upon NIH program administrator determination (NDA or the database of Genotypes and Phenotypes [dbGaP]). Participants will be given the option in the consent/HIPAA form to allow the use of any leftover samples to bank for future undetermined analyses not specified in the protocol.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Human phenotypic data will be uploaded at least twice a year, following NIMH Data Archive (NDA) requirements. Non-human genomes from fecal samples will be shared within 12 months of processing and genotyping all meta-genomes.
Access criteria: Data access will be through the National Institute of Mental Health Data Archive (NDA) and/or the database of Genotypes and Phenotypes (dbGaP).
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Aug 2029, 40 months after the start.
Of 122 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 40 months is above that.
Counting every sponsor, half of 134 studies reached it within 33 months; a quarter within 21 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol
University of Colorado, Denver →